Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD study of PTC844 in healthy adults
NL-OMON60416Phase 1Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PTC844 in autoimmune disease (2 arms), sponsored by PTC Therapeutics, Inc. Primary endpoint: Safety and tolerability. Started Dec 2022; status: completed.
02
Drugs
PTC844
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NL-OMON60416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60416.